Company Filing History:
Years Active: 2025
Title: Jitsutaro Kawaguchi: Innovator in Viral Vector Technology
Introduction
Jitsutaro Kawaguchi is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of viral vector technology, particularly in the development of vectors for gene therapy and regenerative medicine. His innovative work has the potential to impact various therapeutic applications, especially in targeting cancer.
Latest Patents
Kawaguchi holds a patent for a Paramyxovirus vector. The objective of this invention is to provide an improved negative-strand RNA viral vector that exhibits transient high expression of genes loaded in the vector. This technology enables the rapid removal of the vector after gene expression. By adding a micro-RNA target sequence to the NP, P, or L gene of the viral vector, Kawaguchi discovered that it is possible to control the expression of the vector based on the micro-RNA expressed by the introducing cell. Notably, when a micro-RNA target sequence is added to the NP or P gene, the expression of the vector decreases depending on the micro-RNA, promoting the removal of the vector. Conversely, adding a micro-RNA target sequence to the L gene reverses this effect. This vector has promising applications in cell therapy and regenerative medicine, particularly as a therapeutic vector targeting cancer.
Career Highlights
Kawaguchi is associated with Id Pharma Co., Ltd., where he continues to advance his research and development efforts. His work has garnered attention for its innovative approach to gene therapy, positioning him as a key figure in the field.
Collaborations
Kawaguchi has collaborated with notable colleagues, including Koichi Saeki and Kohji Kusano. Their combined expertise contributes to the advancement of viral vector technology and its applications in medicine.
Conclusion
Jitsutaro Kawaguchi's contributions to the field of viral vector technology highlight his innovative spirit and dedication to advancing medical science. His work on the Paramyxovirus vector represents a significant step forward in gene therapy and regenerative medicine.